Director

Garry Nicholson currently serves as chairman of the board of directors for Day One Biopharmaceuticals and Abdera Therapeutics. He also serves on the board of directors for TScan Therapeutics.

Mr. Nicholson previously served on the board of directors for G1 Therapeutics, Turning Point Therapeutics, Five Prime Therapeutics, Tmunity Therapeutics and TESARO prior to their acquisitions by large pharmaceutical companies. As former president of Pfizer Oncology, his responsibilities included global commercialization, sales, clinical development, regulatory strategy and business development for Pfizer’s oncology portfolio. Earlier in his career, Mr. Nicholson held various leadership positions in the oncology division of Eli Lilly and Company, including global oncology platform leader. He has also served as president and CEO of XTuit Pharmaceuticals.

Mr. Nicholson earned a B.S. in Pharmacy from the University of North Carolina at Chapel Hill and an M.B.A. from the University of South Carolina.